Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SHR-1816 in Healthy Subjects
NCT05330208Phase 1Terminated
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd.
- Start
- May 2022
- Primary completion
- Sep 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing SHR-1816 with Placebo (2 arms). Primary endpoints: Number of adverse Events, Incidence of hypoglycemic events and 1 more. Started May 2022; status: terminated.
02
Drugs
shr-1816
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05330208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05330208.